home > ict > spring 2020 > study-life balance: re-envisioning the patient experience
International Clinical Trials

Study-Life Balance: Re-envisioning the Patient Experience

Efforts to improve the patient experience through an enhanced focus on patient-centred care have been driving healthcare conversations for the past few years. Within clinical research, many have long recognised the impact a positive patient experience can have on clinical trial enrolment and engagement. Study sponsors have embraced patient-centric solutions like travel and reimbursement programmes since they were first introduced into the marketplace, recognising their effectiveness at removing barriers to participation and improving the patient’s clinical trial journey.

However, healthcare consumers today are changing. Empowered with new, enhanced technologies, today’s healthcare consumers want convenience, access to information, and immediacy. They have been trained by platforms such as Amazon, OpenTable, and Expedia to expect immediate access to information, and have become accustomed to an ‘on-demand’ model for services.

Research suggests that we can leverage this insight to further enhance the clinical trial patient experience. For too long, many have argued that the clinical trial patient experience should be approached differently to the healthcare consumer experience, arguing that what works to engage healthcare consumers will not work to engage clinical trial participants. A recent Study Voices survey, however, dispels this myth and revealed unexpected similarities between the two groups.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Jessica Kim is the Director of Research and Digital Strategy for BBK Worldwide. Through the assessment of key industry data and trends, Jessica spearheads the development of new engagement strategies to relieve pressure points and enhance the clinical trial patient and site experience. Under her leadership, BBK Worldwide has introduced the new construct of study-life balance to the marketplace along with a comprehensive range of strategies to meet patient needs.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates

OXFORD, UK and SAN JOSE, California, 13/06/2022 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced a multi-year collaboration to research, develop and commercialize novel, first-in-class ADCs with ImmunoGen (IMGN), a leader in the expanding field of ADCs for the treatment of cancer. The companies will utilize ImmunoGen’s linker-payload technology directed to novel targets identified via OBT's proprietary OGAP® discovery platform. The companies will support these R&D efforts through joint funding and by combining their respective proprietary technologies.
More info >>

White Papers



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement